Quentin Clemens, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company:
    Lundbeck
    Date added:
    Date updated:
    09/16/2024
    Relationship end date:
    09/15/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    09/16/2024
    Relationship end date:
    11/12/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company:
    Glaxo Smith Kline
    Date added:
    Date updated:
    09/16/2024
    Relationship end date:
    12/31/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company:
    UroCure
    Date added:
    Date updated:
    09/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (General Urology)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    09/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company:
    Atellas
    Date added:
    Date updated:
    09/16/2024
    Relationship end date:
    03/01/2021
Return to Update Series (2022) Lesson 25: New Developments in Interstitial Cystitis/Bladder Pain Syndrome